Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Group I Pulmonary Arterial Hypertension (a type of high blood pressure in the lungs) that is linked to a connective tissue disease (conditions that affect the body's connective tissues, such as lupus, scleroderma, or rheumatoid arthritis) — whether newly diagnosed or diagnosed some time ago.
- People who have been diagnosed with Group IV pulmonary hypertension linked to a connective tissue disease, where there is also evidence of long-term blood clot disease in the lungs, confirmed by specific lung imaging scans, and who have been on blood-thinning medication for at least three months — whether newly diagnosed or diagnosed some time ago.
- People whose connective tissue disease has been formally diagnosed using the classification guidelines set by the American College of Rheumatology.
- People whose lung blood pressure condition has been confirmed through a procedure called a right heart catheterisation, showing specific pressure and resistance measurements that fall within defined ranges (confirm with trial site for exact values).
Who may not be able to join:
- People whose pulmonary hypertension (high blood pressure in the lungs) falls into Group II, III, or V — meaning it is caused by left heart disease, lung disease, unclear causes, or other complex conditions.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jose Luis Hernandez Oropeza, PhD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phone: +52 55 5487 0900
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To characterize the clinical clinical course of Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) in a register of Mexican patients from the first visit and at every 6 months.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.